Polish Drug Prices Up This Month
The prices of a number of drugs rose 25% in Poland on August 1, reports the PAP news agency. Prices of drugs in the "basic" category rose to $0.44 each, while those obtained under prescription rose to $1 each. There were no price rises for other medicines.
A Ministry of Health official said medicine prices had not changed since February 1995, and that warnings of the price rise had been given in March.
- The vote in the US House of Representatives by 333 to 87 to give Romania permanent Most Favored Nation status will lead to a reduction in US import dues on Romanian medicines, reports the Rompres news agency, and this will in turn lower Romanian producers' costs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze